[1] |
ZHANG Bing, SA Rina, ZHANG Xiaomeng, ZHANG Dan, LIN Zhijian, WANG Yu.
Research progress in pharmacogenic cardiotoxicity
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 841-847.
|
[2] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[3] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[4] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[5] |
CHEN Shuang, ZHENG Shufen, ZHANG Shuyao, ZHONG Shilong.
Adverse reactions of tumor immunotherapy drugs—PD-1/PD-L1 inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1107-1112.
|
[6] |
Chen Aihong, Yin Qiangbing, Li Huadan, Wu Nengjian.
Analysis of Monitoring Reports on Suspected Adverse Events Following Immunization in Pingshan District Shenzhen City during 2015~2018
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 464-468.
|
[7] |
LI Xinxu, TANG Zhimin, ZHOU Jun, WANG Jun.
Limitations of the Safety Assessment in Premarketing Clinical Trials of Drugs and Suggestions for Improvement
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 465-470.
|
[8] |
JIANG RuiJu, YIN QiongZhou, XU MingJue, ZHAO ZhiMei, DENG Yan, NING Ruotong, CHE YanChun.
Adverse Events Induced by Immunization of Concomitant Inoculation of Freeze-dried Hepatitis A (Live) Vaccine with Vaccines for National Immunization Program from Surveillance Data
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 710-714.
|
[9] |
LI Xiaodan, ZHANG Yangxin, LIU Chen, BAI Xiangrong, YAN Suying.
Retrospective Analysis of Adverse Reactions and Prognosis of Six Contrast Agents from 2011 to 2018
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(7): 436-441.
|
[10] |
SUN Yixin, MENG Kangkang, XIA Yukun, XIONG Weiyi, DENG Siwei, DONG Duo, ZHAN Siyan.
Incidence of Cardiac Adverse Events of Cisapride: a Systematic Review and Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 94-100.
|
[11] |
HE Guilin, ZUO Li, WANG Qian.
Comparative Analysis of Adverse Drug Reactions/Adverse Events between Ticagrelor and Clopidogrel
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 52-57.
|
[12] |
ZENG Ling, PAN Xiayun.
Analysis of Adverse Event Records in Quality Control of Drug Clinical Trial Institutions
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 693-695.
|
[13] |
ZHENG Li-jia, ZHAO Yan, DONG Fang.
Medical Device Adverse Events Monitoring and Risk Analysis on Ventilators
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 503-504.
|
[14] |
LI Qing-na ,LU Fang GAO Rui.
Discussion on the Reporting Standards and Quality of Adverse Events in Clinical Researches
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(5): 302-304.
|
[15] |
LIU Bin,ZHAI Wei,ZGONG Lei,ZHAN Si-yan.
Related Factors Analysis of Infusion Pump Safety
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(4): 235-237.
|